中国医药30亿超短期融资券注册获交易商协会接受

Core Viewpoint - The company has received approval for a short-term financing bond registration of 3 billion yuan, which is valid for two years, allowing for phased issuance [1] Group 1 - The company's 2024 annual general meeting approved the proposal to conduct bond and short-term financing bond registration [1] - The company has received a registration acceptance notice from the China Interbank Market Dealers Association [1] - The underwriting will be led by seven banks, including China Merchants Bank and Industrial and Commercial Bank of China [1]